Publicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (22)

2023

  1. Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis

    Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 941-958

  2. Physicians’ attitudes and perceived barriers to adherence to the national breast cancer clinical practice guidelines in Mexico: a survey study

    Clinical and Translational Oncology, Vol. 25, Núm. 1, pp. 151-159

  3. The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review

    Clinical and Translational Oncology, Vol. 25, Núm. 2, pp. 417-428

2022

  1. Immunological Landscape of HER-2 Positive Breast Cancer

    Cancers, Vol. 14, Núm. 13

  2. The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview

    Clinical and Translational Oncology, Vol. 24, Núm. 9, pp. 1744-1754

2021

  1. Oral selective estrogen receptor degraders (Serds) as a novel breast cancer therapy: Present and future from a clinical perspective

    International Journal of Molecular Sciences, Vol. 22, Núm. 15

  2. Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer

    Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5096-5108

2020

  1. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease

    Journal of Clinical Investigation, Vol. 130, Núm. 9, pp. 4871-4887

  2. MicroRNA-33b Suppresses Epithelial–Mesenchymal Transition Repressing the MYC–EZH2 Pathway in HER2+ Breast Carcinoma

    Frontiers in Oncology, Vol. 10

  3. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 3, pp. 203-213

  4. Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)

    European Journal of Cancer Care, Vol. 29, Núm. 4

2019

  1. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    Frontiers in Oncology, Vol. 9, Núm. APR

  2. BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

    Journal of Patient-Reported Outcomes, Vol. 3, Núm. 1

  3. Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases

    Breast Cancer Research and Treatment, Vol. 178, Núm. 2, pp. 251-261

  4. Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy

    Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1548-1556

  2. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

    Oncotarget, Vol. 9, Núm. 41, pp. 26406-26416

2017

  1. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer

    Cancer Research, Vol. 77, Núm. 9, pp. 2213-2221

2015

  1. Lower breast cancer risk among women following the World Cancer Research Fund and American Institute for Cancer Research lifestyle recommendations: Epigeicam case-control study

    PLoS ONE, Vol. 10, Núm. 5

2014

  1. MicroRNA profile in very young women with breast cancer

    BMC Cancer, Vol. 14, Núm. 1